Cardio-Oncology


A thorough understanding of cardio-oncology is very essential for the effective treatment of cancer patients. Virtually all antineoplastic agents are related with cardio toxicity. All patients who are being considered for chemotherapy, particularly the individuals who have earlier history of heart sickness ought to experience point by point cardiovascular assessment to advance the treatment. Sequential examination of left ventricular systolic function and cardiac biomarkers might also be considered in the selected populations of patient. Cardio-toxic effects of chemotherapy can be decreased by the frequent use of angiotensin-converting inhibitors of enzyme, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy may be taken in patients with a potential hyper-coagulable state related with chemotherapy or malignant growth.



 


    Related Conference of Cardio-Oncology

    May 30-31, 2024

    6th Euro Cardiology Congress

    Vienna, Austria
    May 30-31, 2024

    39th World Congress on Heart Diseases

    Vienna, Austria
    June 20-21, 2024

    5th European Summit on Cardiology Research

    Dublin, Ireland
    July 16-17, 2024

    13th World Heart Congress

    Paris, France
    August 01-02, 2024

    38th World Congress on Heart Diseases

    Montreal, Canada
    September 16-17, 2024

    3rd Global Summit on Cardiology and Cardiac Surgery

    Paris, France
    October 24-25, 2024

    11th International Conference on Interventional Cardiology

    Zurich, Switzerland
    October 30-31, 2024

    7th Global Cardiovascular Research and Clinical Cardiology

    Vancouver, Canada

    Cardio-Oncology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in